Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00064415
Status:
COMPLETED
Last Update Posted:
2012-02-22
First Post:
2003-07-08
Brief Title:
To Evaluate the Long-term Safety of RR-Formoterol in Subjects With COPD
Sponsor:
Sumitomo Pharma America Inc
Organization:
Sumitomo Pharma America Inc
Study Overview
Official Title:
A Multicenter Open-Label Randomized Active-Controlled Parallel Group Chronic Safety Study of RR-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD
Detailed Description:
This was a multicenter open-label randomized active controlled parallel group chronic safety study of arformoterol 50 mcg once daily over a period of 12 months in subjects with COPD This study was previously posted by Sepracor Inc In October 2009 Sepracor Inc was acquired by Dainippon Sumitomo Pharma and in October 2010 Sepracor Incs name was changed to Sunovion Pharmaceuticals Inc
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None